Hannah I Miller (Hannah Miller)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Combination Therapy

Acute Lymphoblastic Leukemia

Top Venues

Journal of the American Chemical Society

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Estefania Rafic, Cindy Ma, Bobby B Shih, Hannah I Miller, Rafael Yuste, Teresa Palomero, Roberto Etchenique
RuBi-Ruxolitinib: A Photoreleasable Antitumor JAK Inhibitor. Journal of the American Chemical Society 146 (19) (2024)
Estefania Rafic, Cindy Ma, Bobby B Shih, Hannah I Miller, Rafael Yuste, Teresa Palomero, Roberto Etchenique
RuBi-Ruxolitinib: A Photoreleasable Antitumor JAK Inhibitor. Journal of the American Chemical Society (2024)
Estefania Rafic, Cindy Ma, Bobby B Shih, Hannah I Miller, Rafael Yuste, Teresa Palomero, Roberto Etchenique
RuBi-Ruxolitinib: A Photoreleasable Antitumor JAK Inhibitor. Journal of the American Chemical Society 146 (19) (2024)
Clara Reglero, Chelsea L Dieck, Arie Zask, Farhad Forouhar, Anouchka P Laurent, Wen-Hsuan Wendy Lin, Robert Albero, Hannah I Miller, Cindy Ma, Julie M Gastier-Foster, Mignon L Loh, Liang Tong, Brent R Stockwell, Teresa Palomero, Adolfo A Ferrando
Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia. Cancer discovery 12 (11) (2022)
Marissa Rashkovan, Robert Albero, Francesca Gianni, Pablo Perez-Duran, Hannah I Miller, Adam L Mackey, Elisabeth M Paietta, Martin S Tallman, Jacob M Rowe, Mark R Litzow, Peter H Wiernik, Selina Luger, Maria Luisa Sulis, Rajesh Kumar Soni, Adolfo A Ferrando
Intracellular cholesterol pools regulate oncogenic signaling and epigenetic circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia. Cancer discovery (2021)